行情

ONCS

ONCS

OncoSec医疗
NASDAQ

实时行情|Nasdaq Last Sale

2.200
+0.050
+2.33%
已收盘, 16:00 09/20 EDT
开盘
2.130
昨收
2.150
最高
2.230
最低
2.130
成交量
2.56万
成交额
--
52周最高
19.60
52周最低
1.800
市值
2,335.68万
市盈率(TTM)
-0.0362
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONCS 新闻

  • 品钛上半年净利润1.032亿元 同比增长218%
  • 新浪科技.59分钟前
  • 沙特复产速度遭质疑 美油重上60美元仍可期
  • 汇通网.2小时前
  • 比亚迪:在德国斩获22台12米纯电动大巴订单
  • 新浪财经综合.2小时前
  • 欧元区经济增长接近停滞 制造业重挫的影响开始蔓延
  • 新浪财经综合.2小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ONCS 简况

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
展开

Webull提供OncoSec Medical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。